Drug Trial Radar · NCT01650701
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,030
Actual
Start
Feb 2012
Primary completion
May 31, 2017
Study completion Apr 30, 2024
Sponsor
- Lead sponsor
- The Lymphoma Academic Research OrganisationAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Celgene Corporation
- First posted
- Jul 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment.
Conditions
- Follicular Lymphoma
Interventions
RituximabDrug
• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
LenalidomideDrug
• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
Rituximab - CHOPDrug
six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
Rituximab - CVPDrug
eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
Rituximab - BendamustineDrug
six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- COMPLETE RESPONSE RATETime frame: Timeframe: CR/CRu rate at 120 weeks
- Progression Free Survival (PFS)Time frame: up to 13 years
Locations
35 sites in 8 countries. Site status is shown where the registry gives one.
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Nepean Hospital
Penrith, New South Wales, Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
CHU Mont-Godinne
Yvoir, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Moncton Hospital
Moncton, New Brunswick, Canada
Atlantic Health Sciences Corp - Saint John Regional Hospital
Halifax, Nova Scotia, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
UHN-Princess Margaret Hospital
Toronto, Ontario, Canada
CHUM Hopital Notre-Dame
Montreal, Quebec, Canada
McGill University Department of Oncology
Montreal, Quebec, Canada
Hôpital de l'Enfant-Jesus, CHU de Quebec
Québec, Quebec, Canada
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
CHU Claude Huriez
Lille, France
LMU Munchën - Klinikum Grosshadern
München, Germany
Medizinische Klinik der Universität Tübingen
Tübingen, Baden-Wurttemberg, Germany
Uniklinik Köln
Cologne, Nordrhein, Germany
Policlinico Sant'Orsola-Malpighi
Bologna, Italy
Sant'Andrea Hospital
Rome, Lazio, Italy
Instituto Português Oncologia
Lisbon, Portugal
Hospital Clínico de Barcelona
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Vall d´Hebron
Barcelona, Spain
Institut Català d'Oncologia de Girona (ICO Girona)
Girona, Spain
Hospital Ramon y Cajal
Madrid, Spain
Hospital Costa del Sol
Marbella, Spain
Hospital Universitario Salamanca
Salamanca, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain
Hospital Virgen del Rocio
Seville, Andaloucia, Spain
Hospital Universitario Mutua de Terrassa
Terrassa, Barcelona, Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canary Islands, Spain
Hospital Son Llatzer
Palma, Mallorca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.